

Clinical Note

Patient Name: David Brown
Date of Birth: 1970-09-10
Date of Note: November 18, 2025

Diagnosis & Disease Status

Primary Diagnosis: Colon cancer
ICD-10 Code: C18.9
Disease Stage: Stage III (Note: Assumed based on prior FOLFOX chemotherapy)
Performance Status: ECOG 1 (Assumed)

Clinical History

- Prior Therapies:**
- FOLFOX or 5-FU chemotherapy
- Current Line of Therapy:**
- Second-line or adjuvant

- Medication History:**
- FOLFOX regimen (combination of oxaliplatin, leucovorin, and 5-fluorouracil)

Biomarker & Laboratory Results

Biomarker / Test	Result	Comments
KRAS	Wild type	Eligible for anti-VEGF therapy

Assessment & Plan

Assessment:
Patient with Stage III colon cancer, status post-FOLFOX/5-FU chemotherapy. Biomarker testing indicates KRAS Wild type. Patient is a candidate for anti-angiogenic therapy in the second-line or adjuvant setting.

- Treatment Plan:**
- Planned Treatment:** Bevacizumab
 - Initiate bevacizumab therapy as anti-angiogenic treatment in combination with chemotherapy as indicated.

- Monitor blood pressure, renal function, and proteinuria per bevacizumab safety guidelines.
- Continue surveillance for treatment response and toxicity.

Insurance Information

Provider: Humana

Policy ID: INS33445

Coverage Period: 2025-01-01 to 2025-12-31

Eligibility Status: ACTIVE